Progression of pancreatic neuroendocrine tumors (PanNETs) to metastatic disease is associated with MCT4 expression and metabolic heterogeneity

#3725

Introduction: Up to 50% of patients with PanNETs present with metastasis at time of diagnosis or relapse after surgery, with highly variable dynamics. The mechanisms driving progression from indolent to metastatic disease are largely unknown. Although having great potential for providing novel therapeutic targets, the metabolic landscape at different tumor stages is only poorly understood. Transcriptome and epigenome analyses of PanNET indicate a potential stepwise progression, which is associated with enhanced proliferation, dedifferentiation and hallmarks of hypoxia.

Aim(s): The aim of this study is to classify different metabolic subtypes of PanNET and investigate metabolic targets and their therapeutic potential.

Materials and methods: Immunohistochemical analysis of metabolic enzymes and assessment of microvessel density as correlate for hypoxia were used to classify metabolic subtypes in two independent cohorts.

Conference:

Presenting Author: Sadowski M

Authors: Sadowski M, Bräutigam K, Straub J, Andreasi V, Kirchner P,

Keywords: MCT4, metabolic subtypes, aggressive PanNET, patient-derived tumoroid,